PARP1 and colorectal carcinoma: As shown in Figs. 7 and 9, OSBPL2 deficiency can ameliorate the sensitivity of CRC to PARP1 inhibitors, and the PARP1 inhibitor AG14361 could eliminate metastasis induced by OSBPL2 defect.